A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker

Nenhuma Miniatura disponível
Data
2016
Autores
Aguiar, Pedro N., Jr. [UNIFESP]
Santoro, Ilka Lopes [UNIFESP]
Tadokoro, Hakaru [UNIFESP]
Lopes, Gilberto de Lima
Filardi, Bruno Andraus [UNIFESP]
Oliveira, Pedro
Castelo-Branco, Pedro
Mountzios, Giannis
de Mello, Ramon Andrade
Orientadores
Tipo
Artigo
Título da Revista
ISSN da Revista
Título de Volume
Resumo
Background: Recent studies with nivolumab (a monoclonal antibody against programmed cell death 1 [PD-1] receptor) have shown promise non-small-cell lung cancer (NSCLC) treatment. Methods: To review available clinical trials data in order to assess nivolumab efficacy and the role of tumoral PDL-1 expression as a biomarker. Results: Nine eligible studies included 2102 patients. In the second line setting, nivolumab achieved a 1-year survival rate of 41%
and in the first line, a 1-year survival rate of 76%. For those with PD-L1 expression <1%, nivolumab showed a trend for improved survival compared with docetaxel. Conclusions: The available data reinforce nivolumab activity against NSCLC in first-line or subsequent lines. Although PD-L1 expression is related to greater response, PD-L1 negative patients had also some benefit.
Descrição
Citação
Immunotherapy. London, v. 8, n. 9, p. 1011-1019, 2016.
Coleções